Ngm Biopharmaceuticals Inc Up 0.32% To $1.55 After Earnings Beat

Tuesday, March 12, 2024 - Ngm Biopharmaceuticals Inc (NGM) reported upside earnings and downside revenues.

Ngm Biopharmaceuticals Inc's earnings came in at an EPS loss of $0.33 per share, 15.00% higher than estimates for an EPS loss of $0.39 per share. The firm's loss per share narrowed by 27% since reporting a loss of $0.45 per share a year ago.

Revenues were downbeat at $165 thousand. That represents a 99.09% decrease in revenues from the year-ago report and is 70.54% lower than consensus estimates set at $560 thousand.

The stock is up 0.32% to $1.55 after the report.

Ngm Biopharmaceuticals Inc's revenues declined at a faster pace than earnings.

The average recommendation from Wall Street analysts was a Hold which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 61. Meanwhile, the average Wall Street analyst rated the stock a Hold.

NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.